Naltrexone and Varenicline: Weight Gain and Tolerability in Cigarette Smokers

Phase 1/2 Completed 40 enrolled Yale University National Institute on Alcohol Abuse and Alcoholism (NIAAA) · collab National Institute on Drug Abuse (NIDA) · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine whether the combination of naltrexone (Depade) and varenicline (Chantix) minimizes post-smoking cessation weight gain and how well the combination is tolerated.

Timeline

Start: 2007-07
Primary completion: 2009-06
Completion: 2009-06

Publications

Livingstone-Banks J, Fanshawe TR, Thomas KH, Theodoulou A, Hajizadeh A, Hartman L, Lindson N. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2023 May 5;5(5):CD006103. doi: 10.1002/14651858.CD006103.pub8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Naltrexone	Small molecule	25 mg	Oral
Background	Varenicline	Small molecule	1 mg	Oral

Naltrexone and Varenicline: Weight Gain and Tolerability in Cigarette Smokers

Summary

Timeline

Publications

Drugs

Indications